Intentions Seeker Stocks: Tesla Motors, Inc. (NASDAQ:TSLA), BB&T Corporation (NYSE:BBT), Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Tesla Motors, Inc. (NASDAQ:TSLA) dropped in previous session as it dropped most in over four months following Deutsche Bank AG cut its purchase recommendation on the stock, saying the electric-car maker’s share price matches most of its growth prospects. Rod Lache, a Deutsche Bank analyst stated that they have been bullish on Tesla’s outlooks, based on the company’s electric vehicle opportunity. “And we believe Tesla could become a dominant player. But at this point, Tesla’s shares appear to already reflect this opportunity.”  Tesla Motors, Inc. (NASDAQ:TSLA) stock hit highest price at $260.24, beginning with a price of $259.52 to finish at 267.88 by a decrease of -4.23% with a day range of $255.34-$260.24. The total market capitalization remained 32.88 Billion, total volume of 6.09 Million shares held in the session was surprisingly higher than its average volume of 3873.32 shares.

BB&T Corporation (NYSE:BBT) Mukesh Mali released that it received regulatory authorization from the Federal Reserve, the FDIC and all required state regulators to acquire Susquehanna Bancshares Inc. The transaction is anticipated to close effective August 1, 2015, and systems conversion is expected during the fourth quarter 2015. Headquartered in Lititz, Pa., Susquehanna has more than 240 branch offices in Pennsylvania, Maryland, New Jersey, and West Virginia. The merger includes $18.7 billion in assets and $13.8 billion in deposits based on March 31, 2015, balances. Shares of BB&T Corporation (NYSE:BBT) opened at $39.98 with 731 million outstanding shares and hit to its highest price of $40.23 during the day and finally closed at $40.34 by scoring -0.05%. In the whole session, it traded on volume of 5.02 Million shares, which turned higher than its average volume.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released that it has commenced an underwritten public offering of shares of its common stock and anticipates to lift gross proceeds of around $125M. As well, Atara Bio anticipates to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares in the offering will be sold by Atara Bio. Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the proposed offering. William Blair & Company, LLC, Canaccord Genuity Group, Inc. and JMP Securities LLC are acting as co-managers. On the other consideration, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) begun last trade with a price of $45.53 and throughout the trading session climbed at $45.80. The day-trade ended with a decrease of -1.95% to finish at $46.32.